We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -18.00 | -0.15% | 12,152.00 | 12,150.00 | 12,154.00 | 12,258.00 | 12,114.00 | 12,114.00 | 937,164 | 15:25:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.56 | 187.91B |
From May 2021 to May 2024
By Jaime Llinares Taboada
AstraZeneca PLC said Tuesday that it has requested an Emergency Use Authorization to the U.S. Food and Drug Administration for its Covid-19 prophylaxis AZD7442.
If granted, AZD7442 would be the first long-acting antibody to receive an EUA for Covid-19 prevention, AstraZeneca said.
Data from a Phase 3 trial showed a 77% reduction in the risk of developing symptomatic Covid-19 with long-acting antibody combination, the pharmaceutical company said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
October 05, 2021 02:28 ET (06:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
